MONTREAL and CHARLOTTE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...
(BPT) - The holiday season can be a stressful time for many people. Travel, family gatherings, reminders of personal loss and much more can lead to high stress and anxiety levels, excessive eating and ...
A sudden, rapid heart rate will send many to the emergency room. Every year, more than 140,000 emergency room visits are related to a specific type of increased heart rate called paroxysmal ...
Etripamil nasal spray (Milestone Pharmaceuticals) continues to show promise as a way for patients to treat their own paroxysmal supraventricular tachycardia (PSVT) without the need for an emergency ...
Milestone Pharmaceuticals MIST announced that the FDA issued a Refusal to File (RTF) letter for the new drug application (NDA) seeking approval for self-administered etripamil nasal spray for the ...
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that CARDAMYST, the first and only FDA-approved self-administered treatment for adults with paroxysmal supraventricular tachycardia, is now ...
A clinical trial led by Weill Cornell Medicine investigators showed that a nasal spray that patients administer at home, without a physician, successfully and safely treated recurrent episodes of a ...
Up to 2 million people in the U.S. experience rapid-fire heartbeats from time to time, and many end up in the hospital for treatment. But an investigational nasal spray may help folks with paroxysmal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results